3D MEDICINES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.08 HKD | -1.53% |
|
-10.94% | -7.33% |
| Mar. 29 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
| Mar. 28 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 567.39 4.43K | Sales 2023 | 634.95 4.96K | Capitalization | 1.57B 12.3B |
|---|---|---|---|---|---|
| Net income 2022 | -1.02B -8B | Net income 2023 | -525M -4.1B | EV / Sales 2022 | 13,423,339 x |
| Net cash position 2022 | 766M 5.99B | Net cash position 2023 | 714M 5.58B | EV / Sales 2023 | 1,355,202 x |
| P/E ratio 2022 |
-1.67
x | P/E ratio 2023 |
-3.02
x | Employees | 198 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.53% | ||
| 1 week | -10.94% | ||
| Current month | +8.26% | ||
| 1 month | +13.83% | ||
| 3 months | +5.04% | ||
| 6 months | -20.45% | ||
| Current year | -7.33% |
1 week
6.69
8.20
1 month
6.018.38
Current year
5.178.45
1 year
4.68131.50
3 years
4.68131.50
5 years
4.68131.50
10 years
4.68131.50
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 13-12-31 |
Jing Zhang
DFI | Director of Finance/CFO | 50 | 20-08-27 |
Zhi Qiang Xue
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tat Pang Lin
BRD | Director/Board Member | 67 | 22-11-30 |
Xin Guang Liu
BRD | Director/Board Member | 63 | 21-06-24 |
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 7.08 | -1.53% | 1,041,000 |
| 24-05-27 | 7.19 | -3.23% | 1,128,000 |
| 24-05-24 | 7.43 | +6.45% | 6,786,500 |
| 24-05-23 | 6.98 | -2.79% | 1,060,000 |
| 24-05-22 | 7.18 | -1.51% | 1,001,000 |
Delayed Quote Hong Kong S.E., May 28, 2024 at 04:08 am EDT
More quotes
3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.33% | 226M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- 1244 Stock
